Norfloxacin
chemical compound, antibiotic
Norfloxacin, sold under the brand name Noroxin among others, is an antibiotic that belongs to the class of fluoroquinolone antibiotics. It is used to treat urinary tract infections, gynecological infections, inflammation of the prostate gland, gonorrhea and bladder infection. Eye drops were approved for use in children older than one year of age.
Norfloxacin is associated with a number of rare serious adverse reactions as well as spontaneous tendon ruptures and irreversible peripheral neuropathy. Tendon problems may manifest long after therapy had been completed and in severe cases may result in lifelong disabilities.
It was patented in 1977 and approved for medical use in 1983.
Medical uses
The initial approval by the U.S. Food and Drug Administration (FDA) in 1986 encompassed the following indications:
Uncomplicated urinary tract infections (including cystitis)
Complicated urinary tract infections (restricted use)
Uncomplicated urethral and cervical gonorrhea (however this indication is no longer considered to be effective by some experts due to bacterial resistance)
Prostatitis due to Escherichia coli.
Syphilis treatment: Norfloxacin has not been shown to be effective in the treatment of syphilis. Antimicrobial agents used in high doses for short periods of time to treat gonorrhea may mask or delay the symptoms of incubating syphilis.
Although fluoroquinolones are sometimes used to treat typhoid and paratyphoid fever, norfloxacin had more clinical failures than the other fluoroquinolones (417 participants, 5 trials).
“Norfloxacin” enters the record as chemical compound, antibiotic. Crown Archives preserves that source wording while asking what Norfloxacin, chemical and compound can confirm, complicate or overturn.
Why this record matters
“Norfloxacin” is worth following because a concise public description often conceals a longer documentary argument. Here, Norfloxacin, chemical and compound provides the most credible route into that argument.
Stable identifiers, scientific names and standards terminology offer the best bridge between this overview and specialist evidence. The source revision retrieved here is dated Jan 29, 2026. The linked authority identifier is Q417897. None of the 0 selected statements returned an explicit reference. The first chronological checks are 1977, 1983 and 1986.
Current terminology should not be projected backward without checking the classification used when the underlying evidence was created. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Norfloxacin”, its source revision and the description used here.
- Expand the search: follow Norfloxacin primary sources, Norfloxacin archive and Norfloxacin research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Norfloxacin”?
- Is the terminology current, historical or disputed?
- Has classification or technical consensus changed since the cited source?
Search terms from this dossier
This entry incorporates text from “Norfloxacin” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.